Logo image of IBS.LS

IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

ELI:IBS - Euronext Lisbon - PTIBS0AM0008 - Common Stock - Currency: EUR

9.32  +0.14 (+1.53%)

Fundamental Rating

4

Overall IBS gets a fundamental rating of 4 out of 10. We evaluated IBS against 50 industry peers in the Hotels, Restaurants & Leisure industry. IBS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IBS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

IBS had positive earnings in the past year.
IBS had a positive operating cash flow in the past year.
IBS had positive earnings in 4 of the past 5 years.
In the past 5 years IBS always reported a positive cash flow from operatings.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

1.2 Ratios

With a Return On Assets value of 2.32%, IBS perfoms like the industry average, outperforming 44.00% of the companies in the same industry.
IBS's Return On Equity of 4.95% is in line compared to the rest of the industry. IBS outperforms 52.00% of its industry peers.
IBS has a Return On Invested Capital of 3.03%. This is in the lower half of the industry: IBS underperforms 64.00% of its industry peers.
IBS had an Average Return On Invested Capital over the past 3 years of 4.73%. This is significantly below the industry average of 10.94%.
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROIC 3.03%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

1.3 Margins

IBS has a Profit Margin (3.72%) which is in line with its industry peers.
IBS's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 4.91%, IBS is doing worse than 60.00% of the companies in the same industry.
In the last couple of years the Operating Margin of IBS has declined.
IBS has a Gross Margin (48.89%) which is comparable to the rest of the industry.
IBS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IBS is destroying value.
IBS has about the same amout of shares outstanding than it did 1 year ago.
IBS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IBS has a worse debt to assets ratio.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 1.98 indicates that IBS is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of IBS (1.98) is comparable to the rest of the industry.
The Debt to FCF ratio of IBS is 6.77, which is on the high side as it means it would take IBS, 6.77 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 6.77, IBS is in line with its industry, outperforming 52.00% of the companies in the same industry.
A Debt/Equity ratio of 0.69 indicates that IBS is somewhat dependend on debt financing.
IBS's Debt to Equity ratio of 0.69 is fine compared to the rest of the industry. IBS outperforms 62.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Altman-Z 1.98
ROIC/WACC0.46
WACC6.53%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 1.38 indicates that IBS should not have too much problems paying its short term obligations.
IBS's Current ratio of 1.38 is fine compared to the rest of the industry. IBS outperforms 80.00% of its industry peers.
IBS has a Quick Ratio of 1.28. This is a normal value and indicates that IBS is financially healthy and should not expect problems in meeting its short term obligations.
IBS has a Quick ratio of 1.28. This is in the better half of the industry: IBS outperforms 78.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.28
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for IBS have decreased strongly by -88.97% in the last year.
The earnings per share for IBS have been decreasing by -13.58% on average. This is quite bad
The Revenue has grown by 10.51% in the past year. This is quite good.
IBS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.46% yearly.
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%

3.2 Future

The Earnings Per Share is expected to grow by 17.95% on average over the next years. This is quite good.
IBS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.37% yearly.
EPS Next Y2.42%
EPS Next 2Y16.4%
EPS Next 3Y17.27%
EPS Next 5Y17.95%
Revenue Next Year9.99%
Revenue Next 2Y8.56%
Revenue Next 3Y8.26%
Revenue Next 5Y6.37%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

IBS is valuated rather expensively with a Price/Earnings ratio of 23.30.
IBS's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of IBS to the average of the S&P500 Index (28.79), we can say IBS is valued inline with the index average.
IBS is valuated rather expensively with a Price/Forward Earnings ratio of 21.97.
IBS's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 21.38. IBS is around the same levels.
Industry RankSector Rank
PE 23.3
Fwd PE 21.97
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

76.00% of the companies in the same industry are more expensive than IBS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.06
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IBS's earnings are expected to grow with 17.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)9.63
PEG (5Y)N/A
EPS Next 2Y16.4%
EPS Next 3Y17.27%

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.45%, IBS is a good candidate for dividend investing.
IBS's Dividend Yield is rather good when compared to the industry average which is at 2.94. IBS pays more dividend than 96.00% of the companies in the same industry.
IBS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.47.
Industry RankSector Rank
Dividend Yield 5.45%

5.2 History

The dividend of IBS is nicely growing with an annual growth rate of 31.58%!
Dividend Growth(5Y)31.58%
Div Incr Years1
Div Non Decr Years1
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 0.2 0.4 0.6

5.3 Sustainability

IBS pays out 122.87% of its income as dividend. This is not a sustainable payout ratio.
The dividend of IBS is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP122.87%
EPS Next 2Y16.4%
EPS Next 3Y17.27%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

More info and screens

IBERSOL SGPS SA

ELI:IBS (4/25/2025, 7:00:00 PM)

9.32

+0.14 (+1.53%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-29 2024-11-29/amc
Earnings (Next)N/A N/A
Inst Owners23.23%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap386.87M
Analysts83.33
Price Target12.16 (30.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.45%
Yearly Dividend0.7
Dividend Growth(5Y)31.58%
DP122.87%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.44%
Min EPS beat(2)-25.74%
Max EPS beat(2)-15.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.23%
Min Revenue beat(2)0.18%
Max Revenue beat(2)10.27%
Revenue beat(4)4
Avg Revenue beat(4)6.97%
Min Revenue beat(4)0.18%
Max Revenue beat(4)10.27%
Revenue beat(8)6
Avg Revenue beat(8)5.69%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.56%
PT rev (3m)0.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.31%
EPS NY rev (3m)-14.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)0.93%
Valuation
Industry RankSector Rank
PE 23.3
Fwd PE 21.97
P/S 0.85
P/FCF 9.06
P/OCF 5.02
P/B 1.13
P/tB 1.58
EV/EBITDA N/A
EPS(TTM)0.4
EY4.29%
EPS(NY)0.42
Fwd EY4.55%
FCF(TTM)1.03
FCFY11.04%
OCF(TTM)1.86
OCFY19.91%
SpS10.95
BVpS8.22
TBVpS5.89
PEG (NY)9.63
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROCE 3.84%
ROIC 3.03%
ROICexc 4.07%
ROICexgc 5.24%
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
FCFM 9.4%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
ROICexc(3y)6.92%
ROICexc(5y)N/A
ROICexgc(3y)9.56%
ROICexgc(5y)N/A
ROCE(3y)5.99%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-20.96%
ROICexc growth 3YN/A
ROICexc growth 5Y-13.96%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 7.55%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 252.85%
Current Ratio 1.38
Quick Ratio 1.28
Altman-Z 1.98
F-Score6
WACC6.53%
ROIC/WACC0.46
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)12.95%
Cap/Sales(5y)11.86%
Profit Quality(3y)143.97%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
EPS Next Y2.42%
EPS Next 2Y16.4%
EPS Next 3Y17.27%
EPS Next 5Y17.95%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%
Revenue Next Year9.99%
Revenue Next 2Y8.56%
Revenue Next 3Y8.26%
Revenue Next 5Y6.37%
EBIT growth 1Y-21.52%
EBIT growth 3YN/A
EBIT growth 5Y-7.51%
EBIT Next Year304.41%
EBIT Next 3Y78.76%
EBIT Next 5Y56.64%
FCF growth 1Y-28.97%
FCF growth 3YN/A
FCF growth 5Y20.7%
OCF growth 1Y-29.99%
OCF growth 3Y45.49%
OCF growth 5Y10.5%